北京若生智能科技有限公司
Drug Database
CA

carbetocin (Lonactene / Duratocin / Pabal)

✓ Approved

Ferring · OXTR · 小分子

什么是 carbetocin？

carbetocin 是一种小分子，由Ferring研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Lonactene, Duratocin, Pabal
公司Ferring
药物类别小分子
分子靶点OXTR
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Ferring

作用机制

分子靶点

carbetocin 作用于 1 个分子靶点：

OXTRoxytocin receptor (OTR, OT-R)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

carbetocin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Pregnancy, puerperium and perinatal conditionsPostpartum haemorrhage✓ Approved

相关研究文献

PubMedAnimal reproduction science2026-09-07

Administering carbetocin before electroejaculation in bulls improves semen quality and increases the number of insemination doses.

Orihuela Juan Carlos JC, Pinczak Andrea A, Ungerfeld Rodolfo R

It was recently reported that administering carbetocin before electroejaculation in rams improves quantitative and qualitative characteristics of fresh semen; therefore, the hypothesis was that its use in bulls improves collection conditions in the field. The aim of the study was to determine whether administering carbetocin 15 min before electroejaculation improves semen yield in bulls, and whether these effects are associated with post-thaw sperm quality and sperm cryoresistance. Semen was collected from 29 Braford bulls in a two-period crossover study. Semen was collected from each bull after administering carbetocin (0.2 mg/100 kg body weight, IV) 15 min before electroejaculation, or without carbetocin (control treatment). The treatments were rotated so that all bulls received both. Carbetocin administered 15 min before electroejaculation slightly enhanced semen mass motility (P = 0.05) and moderately increased the number of calculated insemination doses (P = 0.05) compared to control bulls. In addition, it tended to increase the total number of sperm in the ejaculate, the total number of motile sperm, the number of sperm with functional membranes, and the number of sperm without bent tails in fresh semen, as well as the number of effective insemination doses in thawed semen (P = 0.09, P = 0.07, P = 0.06, P = 0.09, and P = 0.08, respectively). Carbetocin administration before electroejaculation in bulls marginally improved fresh semen quality and quantity, including motility and the number of fresh semen insemination doses. This may support routine use in artificial insemination programs by making the collection process more efficient.

PMID 42705159
阅读全文 →
PubMedCureus2026-09-01

Replacing Routine Oxytocin Infusion With Single-Dose Carbetocin at Elective Caesarean Section: A Service Improvement Evaluation of Postpartum Haemorrhage Outcomes.

Muslim Savera S, Rafique Sumaira S, Sukumaran Suganya S

Background Routine postoperative oxytocin infusion after elective caesarean section can require prolonged intravenous administration, continued monitoring, and additional recovery-area resources. Single-dose carbetocin offers a simplified prophylactic uterotonic regimen, but local evaluation is important when implementing a change in practice. Methods This was a single-centre service improvement evaluation using anonymised aggregate data from women undergoing elective lower-segment caesarean section across two consecutive time periods. The oxytocin cohort included 392 elective caesarean sections performed between 1 August 2022 and 30 September 2023, during which routine prophylaxis consisted of oxytocin according to local practice, typically including postoperative infusion. The carbetocin cohort included 446 elective caesarean sections performed between 1 October 2023 and 31 December 2024, following implementation of single-dose intravenous carbetocin as routine prophylaxis. The primary clinical outcome was significant postpartum haemorrhage, defined as estimated blood loss greater than 1.5 L. The secondary clinical outcome was major postpartum haemorrhage, defined as estimated blood loss greater than 2 L. The service outcome was avoidance of routine postoperative uterotonic infusion. Results A total of 838 elective caesarean sections were included. Significant postpartum haemorrhage occurred in 10 of 392 cases in the oxytocin cohort and 12 of 446 cases in the carbetocin cohort, corresponding to rates of 2.55% and 2.69%, respectively. Major postpartum haemorrhage occurred in 2 of 392 cases in the oxytocin cohort and 4 of 446 cases in the carbetocin cohort, corresponding to rates of 0.51% and 0.90%, respectively. Following implementation of carbetocin, routine postoperative uterotonic infusion was no longer required as part of standard prophylaxis. Conclusion In this service improvement evaluation, replacing routine oxytocin infusion with single-dose carbetocin at elective caesarean section was associated with comparable rates of significant and major postpartum haemorrhage while simplifying postoperative uterotonic administration. The findings support the local safety of this practice change, although interpretation is limited by the retrospective aggregate design and absence of patient-level risk adjustment or additional morbidity outcomes.

PMID 42677188
阅读全文 →
PubMedHealthcare (Basel, Switzerland)2026-08-13

Five-Year Trends in Obstetric Hemorrhage, Hemostatic Management, and Blood Product Utilization at a Tertiary Maternity Center in Kazakhstan: A Retrospective Time-Series Study.

Ayazbekov Ardak A, Kurmanova Almagul A, Khaidarov Saken S, Terlikbayeva Aigul A et al.

Background/Objectives: Obstetric hemorrhage remains a leading cause of maternal morbidity and mortality. We examined five-year institutional trends in the recorded hemorrhage rate, cesarean delivery, uterus-preserving hemostatic procedures, uterotonic and antifibrinolytic use, and blood product consumption at a high-volume tertiary maternity center in Kazakhstan. Methods: This was a retrospective time-series analysis of aggregated annual and monthly records for 2018-2022 (46,554 deliveries). The outcome was hemorrhage as entered on the hemorrhage line of the institutional register against the national threshold of 500 mL after vaginal birth and 1000 mL after cesarean; measured blood loss and severity grade were not recorded, so the study describes incidence rather than severity, and blood product figures are hospital-wide adult transfusion volumes. We calculated rates per 1000 deliveries with Wilson confidence intervals, fitted Poisson regression with delivery volume as an offset to estimate incidence rate ratios (IRRs), compared recorded hemorrhage by delivery route with Fisher's exact test, screened for seasonality and out-of-limit months with process control charts, and correlated the monthly hemorrhage rate with service-use variables before and after detrending, with false-discovery-rate correction. Results: The recorded hemorrhage rate fell from 11.39 to 3.62 per 1000 deliveries (rate ratio 0.318, 95% CI 0.217-0.466; 68.2% relative reduction), an average decline of 27.6% per year (IRR 0.724, 95% CI 0.665-0.788, p < 0.001). No reproducible seasonal pattern was found. The cesarean rate declined from 24.90% to 19.36%. Carbetocin and tranexamic acid use rose several-fold, while red cell volume per delivery fell by about 48%. Raw inverse correlations between medication use and hemorrhage were explained by the shared time trend and did not survive detrending and correction. Conclusions: The center recorded a substantial, statistically robust decline in recorded obstetric hemorrhage alongside expanded pharmacologic prophylaxis and reduced transfusion. Because the data are aggregate and neither placental pathology nor other patient case mix could be measured, the parallel trends cannot show that any intervention caused the fall, and a shift in documentation practice cannot be excluded. The findings support prospective monitoring and patient-level study. Because severe hemorrhage and the surgery used to control it may compromise later fertility, the reproductive outcomes of these women are a priority for further research.

PMID 42588376
阅读全文 →
PubMedNigerian medical journal : journal of the Nigeria Medical Association2026-08-05

A Comparative Study on Oxytocin Versus Carbetocin in Prevention of Primary Postpartum Haemorrhage After Childbirth.

Dasghosh Anwesha A, Datta Subhra Kanti SK, Brahma Rupa R

Postpartum haemorrhage (PPH) remains a leading cause of maternal morbidity and mortality worldwide. Effective prophylactic uterotonic agents are essential for preventing primary PPH after childbirth. The study aims to compare the effectiveness and safety of oxytocin versus Carbetocin in preventing primary PPH following both vaginal and caesarean deliveries in a tertiary care setting in Eastern India. This prospective, open-label, randomized controlled superiority trial was conducted over 18 months (October 2022-March 2024) at B.R. Singh Hospital, Kolkata. One hundred and twenty pregnant women aged 18-35 years with singleton pregnancies ≥37 weeks undergoing normal vaginal delivery or caesarean section were randomized into two groups. The Oxytocin group (n=60) received 10 IU intravenously with a maintenance dose, while the Carbetocin group (n=60) received 100μg intravenously without a maintenance dose. Primary outcomes included total blood loss and incidence of PPH. Secondary outcomes included uterine atony and additional uterotonic requirements, hemodynamic changes, change in hemoglobin levels, and maternal side effects. Carbetocin significantly reduced total blood loss in both delivery modes (p<0.001). PPH incidence was lower with Carbetocin (17.9% vs 29.6% in caesarean delivery; 9.4% vs 27.3% in vaginal delivery). Post-delivery haemoglobin levels were significantly higher, and haemoglobin drop was significantly lower in the Carbetocin group. Uterine atony occurred less frequently with Carbetocin (23.3% vs 43.3%, p<0.05). Carbetocin caused minimal hemodynamic changes compared to the significant hypotensive effects of oxytocin. Carbetocin is superior to oxytocin in preventing primary PPH, offering better efficacy and safety profile through reduced complications.

PMID 42553864
阅读全文 →
PubMedCureus2026-08-02

The Prophylactic Role of Tranexamic Acid in Reducing Blood Loss During Cesarean Delivery: A Prospective Randomized Controlled Trial.

Shree Pragya P, Gupta Roshani R, Sachan Divyata D, Verma Vandana V et al.

Postpartum hemorrhage (PPH) is a major risk associated with cesarean delivery. This randomized controlled trial (RCT) aimed to evaluate the prophylactic role of intravenous tranexamic acid (TXA) in reducing total intraoperative blood loss in women undergoing lower-segment cesarean section (LSCS). The study was conducted at the Autonomous State Medical College, Fatehpur, from September 1, 2024, to March 31, 2025. The primary aim of the trial was to investigate the effect of TXA on perioperative and postoperative blood loss during cesarean section in a low-resource setting. A simple randomization technique was used to allocate 300 participants to either group in a 1:1 ratio. The median estimated blood loss (EBL) was identical in both groups at 450 mL (IQR, 250-1000 mL), as measured by the gravimetric method. The mean EBL was lower in the TXA group (460.33 mL) than in the placebo group (511.93 mL) (p < 0.05). The mean changes in hemoglobin level and packed cell volume (PCV) were similar between the two groups. There was no statistically significant difference between the groups in the need for additional uterotonics (misoprostol, carboprost, or carbetocin). Blood transfusions were required in 4.7% (7 cases) of the TXA group and 9.3% (14 cases) of the placebo group. Gastrointestinal side effects were reported in 42.0% of the TXA group and 37.3% of the placebo group. No thromboembolic events were reported in either group. The mean birth weight and mean APGAR scores at one minute were comparable between the two groups. This study supports the prophylactic use of TXA during cesarean delivery to reduce intraoperative blood loss. The significant reduction in mean EBL, combined with the absence of major adverse effects, underscores the role of TXA as a safe and effective adjunct to standard uterotonic therapy.

PMID 42540384
阅读全文 →
PubMedClinical therapeutics2026-07-23

Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study.

Roof Elizabeth E, Strong Theresa V TV, Stafford Diane E J DEJ, Singh Deepan D et al.

Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by endocrine and neuropsychiatric problems including hyperphagia, anxiousness, and distress. The oxytocinergic system represents one of the key neural circuits that is dysfunctional in PWS, making it an attractive therapeutic target. The oxytocin analog carbetocin has a longer half-life and greater receptor selectivity than oxytocin and showed therapeutic potential in the phase 3 CARE-PWS study (ClinicalTrials.gov NCT03649477) based on nominally significant improvements in hyperphagia and anxiousness with the 3 times daily (TID) 3.2-mg dose of intranasal carbetocin over placebo. The phase 3 placebo-controlled COMPASS PWS study was conducted to confirm the potential benefit observed with carbetocin in the CARE-PWS study. In the 12-week COMPASS PWS study (ClinicalTrials.gov NCT06173531), 175 participants were randomized 1:1 to carbetocin 3.2 mg TID nasal spray (n = 85) and placebo (n = 90). The primary efficacy endpoint was the change from baseline at week 12 in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score. Secondary efficacy endpoints were the change in the Clinical Global Impression-Severity (CGI-S) score for PWS, and in the CGI-S for hyperphagia in PWS score from baseline at week 12, the CGI-Change for PWS score at week 12, and the percentage of participants with a treatment response (defined as improvement from baseline ≥8 points) based on the HQ-CT at week 12. Exploratory efficacy endpoints included the change from baseline at week 12 in scores for the PWS Anxiousness and Distress Behaviors Questionnaire. The least squares mean change (standard error) from baseline at week 12 in the HQ-CT was -4.8 (0.8) and -5.1 (0.8) in the carbetocin and placebo groups, respectively; the treatment difference of 0.3 (95% confidence interval: -1.8, 2.4; P = 0.79) was not statistically significant. There was no separation between carbetocin and placebo for any secondary or exploratory endpoint. The most frequently reported treatment-emergent adverse events in the carbetocin-treated participants were headache (n = 6 [7.2%]) and pyrexia (n = 5 [6.0%]). Carbetocin nasal spray did not demonstrate efficacy compared with placebo for hyperphagia in PWS in the 12-week COMPASS PWS study.

PMID 42486751
阅读全文 →

注册免费账户还可查看另外 413 篇文献

免费注册查看全部文献 →

了解更多carbetocin